Elizabeth O'Day
Dr. Elizabeth O’Day (born January 26, 1984) is an American scientist and entrepreneur who specializes in precision medicine, biotechnology, and female empowerment. She is the CEO and Founder of Olaris Therapeutics, a precision medicine company in Cambridge, MA, that identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare cost.[1] She is a member of the World Economic Forum’s expert network in biotechnology and precision medicine.[2] Dr. O'Day is also the Founder of Lizzard Fashion, Proyecto Chispa, Women in Science and Technology (WST), and PhiSB.[3]
Education
Dr. O'Day graduated from Boston College summa cum laude in 2006, with a bachelor of science degree in biochemistry. As an undergraduate, she conducted research in the laboratory of Dr. Evan Kantrowitz, completing a thesis on the “Design and synthesis of aspartate transcarbamoylase inhibitor compounds”. At Boston College, she also did what few others have done at any university, receiving nearly all of the nation’s top undergraduate awards (Beckman Scholarship, Goldwater Scholarship, Churchill Fellowship and National Science Foundation Fellowship).[4]
Upon graduation from Boston College and as a Winston Churchill Fellow, Dr. O'Day attended the University of Cambridge and received a Master in Philosophy (MPhil) in Chemistry. Working in the laboratory of Professor Chris Dobson, using biophysical methods to investigate the misfolded states of alpha-synuclein, the protein responsible for Parkinson’s Disease, she completed a thesis, “Understanding the interaction between a single heavy chain domain fragment of a camelid antibody and alpha-synuclein.”[5]
Dr. O'Day received a PhD in Biological and Biomedical Sciences from Harvard University in 2013. Her doctoral work accelerated research in cancer biology and structural biology leading to the discovery of unique RNA structures and metabolites in tumor initiating cells, performed in the laboratories of Prof. Judy Lieberman and Professor Gerhard Wagner. It also resulted in a thesis, “Using NMR to identify structural features of Lin28-regulated miRNAs and mRNAs and as a tool for comparing differences is cellular metabolism”.
Career
In 2014, Dr. O'Day founded Olaris Therapeutics and currently serves as its CEO. Olaris's technology is a spin out from Dr. O’Day’s doctoral work at Harvard University. In a single experiment, Olaris’ metabolite profiling platform can map nearly the entire human metabolome.[6]
Adjunct faculty in the Chemistry Department at Boston College, teaching "Human Metabolism, Disease and Entrepreneurship". The class was designed by Dr. O’Day to put a face to the science students learn in the classroom. She combines lectures on metabolic pathways and direct interactions with patients afflicted with metabolic diseases and entrepreneurs developing products to help those patients.[7]
Memberships and Ventures
Founder of "Women in Science & Technology" (WST) at Boston College. WST is in its 12th year and has provided hundreds of high school-aged females and college students the opportunity to learn about careers in science. [8][9]
Member of the Global Future Council on Biotechnologies. Run by the World Economic Forum, the Network of Global Future Councils is an invitation-only knowledge network that serves as a forward-looking brain trust to the World Economic Forum and the world at large. Each of the 35 councils comprises 25 globally renowned experts from business, government, academia and civil society. The network gives its members a platform to support the Forum's vision to better understand and shape global systems in the face of rapid social and technological transformation.[10]
Advisory Board Member at WEST, Women in the Enterprise of Science and Technology. Located in Greater Boston, WEST is a learning community that provides women in the enterprise of science and technology with the inspiration, knowledge, and connections to reach their full potential. Advisory board members provide strategic contributions to accomplish WEST’s mission.[11]
Founder of Lizzard Fashion, an apparel company that uses fashion to promote science. Partial Lizzard proceeds support cancer research.
Founder of Proyecto Chispa (Project Spark), a 501c3 non-profit that recycles electronics and uses the resale of parts to build computer centers in orphanages throughout the world.[12] Founder of PhiSB. An invitation only network of females that aims to connect and celebrate amazing women across the globe.[13]
Frequent speaker on entrepreneurship and women empowerment at events including StartUp Leadership, The Broad, Massachusetts Institute of Technology, MassBio, Tufts University, Boston College, AAUW, and Quest’s NextGen Leaders.[14] [15] [16]
Awards and Recognitions
2006: Rev. Edward Finnegan, SJ Award Winner, considered the most prestigious honor bestowed to an undergraduate, selected as the student who most exemplifies the Boston College motto “Ever to Excel”.[17]
2006: Awarded Barry M. Goldwater Scholarship, national undergraduate fellowship selected on the ability to design and execute research in the natural sciences.
2006: Awarded Arnold Beckman Scholarship, national undergraduate scholarship selected based on accomplishments that contribute to the advancement of chemistry and biological sciences.[18]
2007: One of eleven American scientists awarded a Winston Churchill Fellowship.
2007: Awarded a National Science Foundation Graduate Research Fellowship.
2015: Selected as the Greenovate Champion of the Year by the Mayor of Boston, Martin J. Walsh.[19]
2016: Invited to attend Vice President Joe Biden's Cancer Moonshot 2020 Summit in Washington, DC to discuss collaborative ways “to end cancer as we know it”.
2016: Named World Economic Forum Global Shaper.[20]
2016: Invited speaker as a “new champion to reboot healthcare” at the annual meeting in Davos.
2016: Named one of “the women of the year” by TruTV in Beirut, Lebanon.
2016: Invited Speaker at Intelligence of the World, Europe and Italy Forum, Cernobbio, Italy. Selected as one of only 200 people worldwide to attend this annual event of international scope and prestige. Heads of state and government, top representatives of European institutions, ministers, Nobel prize winners, businessmen, managers and experts from around the world meet every year since 1975 to discuss current issues of major impact for the world economy and society as a whole.
2016: Invited attendee at the United State of Women Summit, Washington DC. Nominated Change-maker and invited to attend the first ever United State of Women Summit convened by the White House to rally and celebrate the achievements of women and develop action plans for the future.
2016: Boston Delegate at City Awake, a platform designed to mobilize and empower young adults to become valued stakeholders in the civic dialogue of Greater Boston.
2017: Invited to World Economic Forum Global Future Council on Biotechnology.
2017: Invited speaker on precision medicine with a strategic session with Prime Minister’s Office in the United Arab Emirates.
2018: Recognized as a “Unsung Hero Doing Extraordinary Things” by WEST honoring women and men making an impact in society.[21]
Associations
• Order of the Cross & Crown - Honor Society
• World Economic Forum Expert Network
• Steering Committee for the World Economic Forum’s Precision Medicine Initiative
Selected Publications
• O'Day E, Le MT, Imai S, Tan SM, Kirchner R, Arthanari H, Hofmann O, Wagner G, Lieberman J. (2015) An RNA-binding Protein, Lin28, Recongizes and Remodels G-quartets in the MicroRNAs (miRNAs) and mRNAs it Regulates, J Biol Chem, July 17;290(29):17909-22.[22]
• Elizabeth M. O’Day, Pavel Ivanov, Gerhard Wagner, Judy Lieberman and Paul Anderson. (2014) G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments, Proc Natl Acad Sci Dec 23;111(51):18201-6.[23]
• Eldo, J., Cardia, J.P., O’Day, E.M. Xia, J., Tsuruta, H., Kantrowitz, E.R. (2006) N-phosphonacetyl-L-isoasparagine a potent and specific inhibitor of Escherichia coli aspartate transcarbamoylase. J Med Chem 49, 5932-8.[24]
• Guilliams T1, El-Turk F, Buell AK, O'Day EM, Aprile FA, Esbjörner EK, Vendruscolo M, Cremades N, Pardon E, Wyns L, Welland ME, Steyaert J, Christodoulou J, Dobson CM, De Genst E. (2013) Nanobodies Raised against Monomeric α-Synuclein Distinguish between Fibrils at Different Maturation Stages[25]
• Luna RE1, Arthanari H, Hiraishi H, Nanda J, Martin-Marcos P, Markus MA, Akabayov B, Milbradt AG, Luna LE, Seo HC, Hyberts SG, Fahmy A, Reibarkh M, Miles D, Hagner PR, O'Day EM, Yi T, Marintchev A, Hinnebusch AG, Lorsch JR, Asano K, Wagner G. (2012) The C-terminal domain of eukaryotic initiation factor 5 promotes start codon recognition by its dynamic interplay with eIF1 and eIF2β[26]
• Lal A1, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, Concepcion C, Han YC, Thiery J, Rajani DK, Deutsch A, Hofmann O, Ventura A, Hide W, Lieberman J. (2011) Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling.[27]
• Yan N1, O'Day E, Wheeler LA, Engelman A, Lieberman J. (2011) HIV DNA is heavily uracilated, which protects it from autointegration.[28]
• Le MT1, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J, O'Day E, Korzh V, Yang H, Lal A, Lieberman J, Lodish HF, Lim B. (2011) Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs[29]
• O'Day E1, Lal A. (2010) MicroRNAs and their target gene networks in breast cancer.[30]
• De Genst EJ1, Guilliams T, Wellens J, O'Day EM, Waudby CA, Meehan S, Dumoulin M, Hsu ST, Cremades N, Verschueren KH, Pardon E, Wyns L, Steyaert J, Christodoulou J, Dobson CM. (2010) Structure and properties of a complex of α-synuclein and a single-domain camelid antibody.[31]
• Vuchelen A1, O'Day E, De Genst E, Pardon E, Wyns L, Dumoulin M, Dobson CM, Christodoulou J, Hsu ST. (2009) (1)H, (13)C and (15)N assignments of a camelid nanobody directed against human alpha-synuclein.[32]
• Lal A1, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, Becker KG, Gorospe M, Hide W, Lieberman J. (2009) miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements.[33]
• West JM1, Xia J, Tsuruta H, Guo W, O'Day EM, Kantrowitz ER. (2008) Time evolution of the quaternary structure of Escherichia coli aspartate transcarbamoylase upon reaction with the natural substrates and a slow, tight-binding inhibitor.[34]
• Cardia JP1, Eldo J, Xia J, O'Day EM, Tsuruta H, Gryncel KR, Kantrowitz ER. (2008) Use of L-asparagine and N-phosphonacetyl-L-asparagine to investigate the linkage of catalysis and homotropic cooperativity in E. coli aspartate transcarbomoylase.[35]
References
- ↑ "Scientist Elizabeth O'Day talks to Youmna Naufal". You Tube. Retrieved 22 January 2018.
- ↑ "World Economic Forum". www.weforum.org. Retrieved 22 January 2018.
- ↑ "Braintree's Liz O'Day uses fashion to show that science is cool". www.patriotledger.com. Retrieved 22 January 2018.
- ↑ "The Decade at a Glance". www.bc.edu. Retrieved 22 January 2018.
- ↑ "England? India? Hard Choice for WST Organizer". www.bc.edu. Retrieved 22 January 2018.
- ↑ "Who Are the Women of Davos 2016?". Alarabiya English. Retrieved 22 January 2018.
- ↑ "Show of Force; Scientist, educator, and advocate Liz O'Day '06 takes an entrepreneurial approach to fighting disease". www.bc.edu. Retrieved 22 January 2018.
- ↑ "Women in Science". www.bc.edu. Retrieved 22 January 2018.
- ↑ "BC Unveils Women in Science & Technology Program Senior spearheads initiative to spur girls' interest in science". www.bc.edu. Retrieved 22 January 2018.
- ↑ "The Future of Biotechnologies". World Economic Forum. Retrieved 22 January 2018.
- ↑ "Advisory Board". WEST Women in the Enterprise of Science and Techonology. Retrieved 22 January 2018.
- ↑ "E-Waste Collection Site". Impact Hub. Retrieved 22 January 2018.
- ↑ "PhiSB Members". PhiSB. Retrieved 22 January 2018.
- ↑ "Speaker". Speakerhub. Retrieved 22 January 2018.
- ↑ "Sackler of Graduate Biomedical Sciences". sackler.tufts.edu. Retrieved 22 January 2018.
- ↑ "MBG Lunch Seminar with Liz O'Day, CEO and Founder of Olaris Therapeutics". MIT Biotech Group. Retrieved 22 January 2018.
- ↑ "An Honor to End All Honors Finnegan Award is the crowning achievement for BC seniors". www.bc.edu. Retrieved 22 January 2018.
- ↑ "Enzymes and ambitions Biochemist, 22, already making contributions". Boston.com. Retrieved 22 January 2018.
- ↑ "Mayor Walsh Hosts Greenovate Boston Community Summit". Boston.gov. Retrieved 22 January 2018.
- ↑ "Boston Hub - Meet the Shapers". Global Shapers Community. Retrieved 22 January 2018.
- ↑ "WEST's 10th Annual "Giving Back" Awards Ceremony #WESTawards". WEST Women in the Enterprise of Science and Technology. Retrieved 22 January 2018.
- ↑ "An RNA-binding Protein, Lin28, Recognizes and Remodels G-quartets in the MicroRNAs (miRNAs) and mRNAs It Regulates". Pubmed.gov. US National Library of Medicine National Institutes of Health. Retrieved 22 January 2018.
- ↑ "G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments". PubMed Central. National Center for Biotechnology Information. Retrieved 22 January 2018.
- ↑ "N-phosphonacetyl-L-isoasparagine a potent and specific inhibitor of Escherichia coli aspartate transcarbamoylase". PubMed. US National Library of Medicine National Institutes of Health. Retrieved 22 January 2018.
- ↑ "Nanobodies Raised against Monomeric α-Synuclein Distinguish between Fibrils at Different Maturation Stages". Science Direct. Retrieved 22 January 2018.
- ↑ "The C-Terminal Domain of Eukaryotic Initiation Factor 5 Promotes Start Codon Recognition by Its Dynamic Interplay with eIF1 and eIF2β". ScienceDirect. Retrieved 22 January 2018.
- ↑ "Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling". PubMed. US National Library of Medicine National Institutes of Health.
- ↑ "HIV DNA is heavily uracilated, which protects it from autointegration". PNAS - Proceeding of the National Academy of Sciences of the United States of America. Retrieved 22 January 2018.
- ↑ "Conserved Regulation of p53 Network Dosage by MicroRNA–125b Occurs through Evolving miRNA–Target Gene Pairs". PLOS Genetics. Retrieved 22 January 2018.
- ↑ "MicroRNAs and their target gene networks in breast cancer". BMC BioMed Central. Retrieved 22 January 2018.
- ↑ "Structure and properties of a complex of α-synuclein and a single-domain camelid antibody". PubMed. US National Library of Medicine National Institutes of Health.
- ↑ "1H, 13C and 15N assignments of a camelid nanobody directed against human α-synuclein". Springer Link. Retrieved 22 January 2018.
- ↑ "miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements". PubMed. US National Library of Medicine National Institutes of Health.
- ↑ "Time evolution of the quaternary structure of Escherichia coli aspartate transcarbamoylase upon reaction with the natural substrates and a slow, tight-binding inhibitor". PubMed.gov. US National Library of Medicine National Institutes of Health.
- ↑ "Use of L-asparagine and N-phosphonacetyl-L-asparagine to investigate the linkage of catalysis and homotropic cooperativity in E. coli aspartate transcarbomoylase". PubMed.gov. US National Library of Medicine National Institutes of Health. Retrieved 22 January 2018.
This article "Elizabeth O'Day" is from Simple English Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Elizabeth O'Day.
